- Home
- SER vs PYXS Comparison
SER vs PYXS Comparison
Compare SER & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- PYXS
- Stock Information
- Founded
- SER 2017
- PYXS 2018
- Country
- SER United States
- PYXS United States
- Employees
- SER N/A
- PYXS N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- PYXS Health Care
- Exchange
- SER Nasdaq
- PYXS Nasdaq
- Market Cap
- SER 56.5M
- PYXS 66.3M
- IPO Year
- SER 2018
- PYXS 2021
- Fundamental
- Price
- SER $5.75
- PYXS $1.33
- Analyst Decision
- SER Strong Buy
- PYXS Strong Buy
- Analyst Count
- SER 1
- PYXS 5
- Target Price
- SER $11.00
- PYXS $9.00
- AVG Volume (30 Days)
- SER 10.4K
- PYXS 416.4K
- Earning Date
- SER 05-08-2025
- PYXS 05-15-2025
- Dividend Yield
- SER N/A
- PYXS N/A
- EPS Growth
- SER N/A
- PYXS N/A
- EPS
- SER N/A
- PYXS N/A
- Revenue
- SER $51,000.00
- PYXS N/A
- Revenue This Year
- SER N/A
- PYXS N/A
- Revenue Next Year
- SER N/A
- PYXS N/A
- P/E Ratio
- SER N/A
- PYXS N/A
- Revenue Growth
- SER N/A
- PYXS N/A
- 52 Week Low
- SER $3.81
- PYXS $0.83
- 52 Week High
- SER $14.57
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- SER 54.81
- PYXS 56.20
- Support Level
- SER $5.01
- PYXS $1.20
- Resistance Level
- SER $6.00
- PYXS $1.27
- Average True Range (ATR)
- SER 0.32
- PYXS 0.07
- MACD
- SER 0.01
- PYXS 0.00
- Stochastic Oscillator
- SER 81.65
- PYXS 83.33
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.